Posters
XEN45 Gel Stent implant: results in primary open-angle glaucoma vs secondary open-angle glaucoma
Poster Details
First Author: N.Moura-Coelho PORTUGAL
Co Author(s): S. Crisostomo L. Costa A. Basi��lio M. Dutra-Medeiros M. Sa Cardoso T. Gomes
Abstract Details
Purpose:
To evaluate and compare the efficacy and safety of the XEN45 Gel Stent Glaucoma Treatment System (Allergan, Irvine, CA) between patients with primary open-angle glaucoma (POAG) and patients with secondary open-angle glaucoma (SOAG).
Setting:
The study was conducted at a tertiary center for Ophthalmology in Portugal, and reports the initial experience with XEN implantation at the national level.
Methods:
Retrospective analysis of 19 eyes of 18 patients with medically refractory open-angle glaucoma who underwent XEN implantation at our institution. Clinical outcomes measured at 6-month follow-up included intra-ocular pressure (IOP) reduction, IOP reduction rate, reduction in number IOP-lowering drug requirements, required additional procedures, and complications.
Results:
11 eyes with POAG and 8 eyes with SOAG underwent XEN implant surgery. A significant reduction in IOP at 6-month post-surgery was observed in both POAG and SOAG patient groups (p-value = 0.021, p-value = 0.018, respectively). The median difference in IOP reduction between both groups was not statistically significant (p-value = 0.620), as were not median IOP reduction rate and the median reduction in IOP-lowering drug requirements post-operatively (p-value = 0.869 and p-value = 0.933, respectively). No major intra-operative or post-operative complications were observed; 3 patients in each group required additional procedures within the follow-up period.
Conclusions:
In this study, the XEN stent showed good efficacy and safety profiles in lowering the IOP, with similar outcomes in both primary and secondary open-angle glaucoma. Larger, prospective studies are needed to further understand whether etiology of OAG may play a role in XEN surgery outcomes.
Financial Disclosure:
NONE
